公开(公告)号：US20210260040A1

公开(公告)日：2021-08-26

申请号：US16756304

申请日：2018-10-18

Applicant: Epizyme, Inc.

Inventor： Elayne PENEBRE ,  Veronica GIBAJA ,  Maria Alejandra RAIMONDI

IPC: A61K31/4184 ,  A61K31/17 ,  A61K31/167 ,  A61K31/496 ,  A61K31/4965 ,  A61K31/706 ,  A61K31/165 ,  A61K31/454 ,  A61K31/155 ,  A61K38/46 ,  A61K31/198 ,  A61P7/06 ,  A61K31/407 ,  A61K31/428 ,  A61K31/437 ,  A61K31/519 ,  A61K31/506 ,  A61K31/4985 ,  A61K31/4709 ,  A61K31/4192 ,  A61K31/4406 ,  A61K31/4045

Abstract: The present disclosure relates to a method of preventing or treating a blood disorder (e.g., sickle-cell disease) via administering an EHMT2 inhibitor compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.

公开(公告)号：US20240180880A1

公开(公告)日：2024-06-06

申请号：US18454612

申请日：2023-08-23

Applicant: Epizyme, Inc.

Inventor： Elayne PENEBRE ,  Veronica GIBAJA ,  Maria Alejandra RAIMONDI

IPC: A61K31/4184 ,  A61K31/155 ,  A61K31/165 ,  A61K31/167 ,  A61K31/17 ,  A61K31/198 ,  A61K31/4045 ,  A61K31/407 ,  A61K31/4192 ,  A61K31/428 ,  A61K31/437 ,  A61K31/4406 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/4965 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/519 ,  A61K31/706 ,  A61K38/46 ,  A61P7/06 ,  C07C211/44 ,  C07C211/45 ,  C07C211/46 ,  C07C211/47 ,  C07C211/48

CPC classification number: A61K31/4184 ,  A61K31/155 ,  A61K31/165 ,  A61K31/167 ,  A61K31/17 ,  A61K31/198 ,  A61K31/4045 ,  A61K31/407 ,  A61K31/4192 ,  A61K31/428 ,  A61K31/437 ,  A61K31/4406 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/4965 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/519 ,  A61K31/706 ,  A61K38/465 ,  A61P7/06 ,  C07C211/44 ,  C07C211/45 ,  C07C211/46 ,  C07C211/47 ,  C07C211/48

Abstract: The present disclosure relates to a method of preventing or treating a blood disorder (e.g., sickle-cell disease) via administering an EHMT2 inhibitor compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.

公开(公告)号：US20230087806A1

公开(公告)日：2023-03-23

申请号：US17474581

申请日：2021-09-14

Applicant: Epizyme, Inc.

Inventor： John Emmerson CAMPBELL ,  Kenneth William DUNCAN ,  Elayne PENEBRE ,  Kat COSMOPOULOS ,  Christine KLAUS

IPC: A61K31/506 ,  A61K31/4155 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/501 ,  A61K31/505 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/553 ,  A61K45/06

Abstract: The present disclosure relates to a method of preventing or treating an imprinting disorder via administering an EHMT2 inhibitor compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.

公开(公告)号：US20230364086A1

公开(公告)日：2023-11-16

申请号：US18188691

申请日：2023-03-23

Applicant: Epizyme, Inc.

Inventor： John Emmerson CAMPBELL ,  Kenneth William DUNCAN ,  Maria Alejandra RAIMONDI ,  Christine KLAUS ,  Elayne PENEBRE

IPC: A61K31/506 ,  A61P35/00 ,  A61K31/203 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/496 ,  A61K31/517 ,  A61K31/519 ,  A61K31/706

CPC classification number: A61K31/506 ,  A61P35/00 ,  A61K31/203 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/496 ,  A61K31/517 ,  A61K31/519 ,  A61K31/706

Abstract: The present disclosure relates to a method of preventing or treating a cancer via administering an EHMT2 inhibitor or a combination comprising an EHMT2 inhibitor compound and one or more additional therapeutic agent disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds or combinations for research or other non-therapeutic purposes.

公开(公告)号：US20210213014A1

公开(公告)日：2021-07-15

申请号：US16756566

申请日：2018-10-18

Applicant: Epizyme, Inc.

Inventor： Kat COSMOPOULOS ,  Elayne PENEBRE

IPC: A61K31/506 ,  A61K31/4545 ,  A61K31/444 ,  A61K31/5377 ,  A61K31/5513 ,  A61K31/541 ,  A61K31/52 ,  A61K31/416 ,  A61K31/437 ,  A61K31/5025

Abstract: The present disclosure relates to methods and compositions for treating immune-mediated diseases. In some aspects, the disclosure relates to methods for treating immune-mediated diseases by administering an EHMT2 inhibitor in combination with one or more treatment modalities (e.g. one or more therapeutic agents). In some aspects the immune-mediated disease is rheumatoid arthritis, multiple sclerosis, psoriasis, a psoriatic disorder, psoriatic arthritis, or an inflammatory bowel disease.

公开(公告)号：US20200054635A1

公开(公告)日：2020-02-20

申请号：US16606833

申请日：2018-04-20

Applicant: Epizyme, Inc.

Inventor： John Emmerson CAMPBELL ,  Kenneth William DUNCAN ,  Maria Alejandra RAIMONDI ,  Christine KLAUS ,  Elayne PENEBRE

IPC: A61K31/506 ,  A61K31/203 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/496 ,  A61K31/517 ,  A61K31/519 ,  A61K31/706 ,  A61P35/00

Abstract: The present disclosure relates to a method of preventing or treating a cancer via administering an EHMT2 inhibitor or a combination comprising an EHMT2 inhibitor compound and one or more additional therapeutic agent disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds or combinations for research or other non-therapeutic purposes.